BRIEF-Bristol Myers Squibb Says Phase 3 Successor-2 Trial Shows MeziKd Achieves 18-Month Median PFS

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY

0.00

May 29 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB: MEZIKD REDUCES DISEASE PROGRESSION/DEATH RISK BY OVER 50% VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

  • BRISTOL MYERS SQUIBB: PHASE 3 SUCCESSOR-2 TRIAL SHOWS MEZIKD ACHIEVES 18-MONTH MEDIAN PFS

  • BRISTOL MYERS SQUIBB: SIGNIFICANTLY IMPROVED PFS RATES WITH MEZIKD ACROSS PATIENTS IN SECOND- & THIRD-LINE AND THOSE WITH HIGHER-RISK DISEASE

  • BRISTOL MYERS SQUIBB: HIGHER OVERALL RESPONSE RATE AND COMPLETE RESPONSE OR BETTER WERE SEEN WITH MEZIKD

  • BRISTOL MYERS SQUIBB: MEDIAN OVERALL SURVIVAL WAS NOT YET REACHED WITH MEZIKD IN PHASE 3 SUCCESSOR-2 TRIAL

  • BRISTOL MYERS SQUIBB: SAFETY PROFILE OF MEZIKD WAS CONSISTENT WITH KNOWN PROFILE OF MEZIGDOMIDE COMBINATION REGIMEN



Further company coverage: BMY.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.